Please assess the completion status of the following clinical trial:

Trial Title: Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Treatment naive males and females, \>= 18 years old and~\<= 77 years old, with type 2 diabetes mellitus~* Subjects must have central laboratory pre-randomization hemoglobin A1C \>= 7.5 and \<= 12.0%~* C-peptide \>= 1.0 ng/mL (0.34 nmol/L)~* Body Mass Index \<= 45 kg/m2~* Must be able to perform self monitoring of blood glucose~Exclusion Criteria:~* aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \>3X\*upper limit of normal (ULN)~* Serum Total bilirubin \>2 mg/dL (34.2 µmol/L)~* Creatinine kinase \>3\*ULN~* Serum creatinine \>= 1.50 mg/dL (133 µmol/L) for male subjects, \>= 1.40 mg/dL (124 µmol/L) for female subjects~* Calcium value outside of the central laboratory normal reference range~* Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric, or rheumatic diseases~* Urine albumin:creatinine ratio (UACR) \>1800 mg/g (203.4 mg/mmol Cr)~* Severe uncontrolled hypertension defined as systolic blood pressure (SBP) \>=180 mmHg and/or diastolic blood pressure (DBP) \>=110 mmHg~* Hemoglobin \>=11.0 g/dL (110 g/L) for men; hemoglobin \>=10.0 g/dL (100 g/L) for women~* Positive for hepatitis B surface antigen~* Positive for anti-hepatitis C virus antibody~* History of diabetes insipidus~* History of diabetic ketoacidosis or hyperosmolar nonketotic coma~* Symptoms of poorly controlled diabetes that would preclude participation in this trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 77 Years
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin + Metformin XR (Type: EXPERIMENTAL): Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks~Metformin XR: Tablets, Oral, up to 2000 mg, once daily, 24 weeks
- Dapagliflozin + Placebo (Type: EXPERIMENTAL): Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks.~Placebo: Metformin HCl Modified Release matching placebo tablets, once daily, 24 weeks.
- Metformin XR + Placebo (Type: ACTIVE_COMPARATOR): Metformin XR: Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks~Placebo: Dapagliflozin matching placebo tablets once daily, 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).